Effectiveness of calcimimetics on fractures in dialysis patients with secondary hyperparathyroidism: meta-analysis of randomized trials

被引：3

作者：

Wakamatsu, Takuya ^{[1
]}

Yamamoto, Suguru ^{[2
]}

Matsuo, Koji ^{[3
]}

Taniguchi, Masatomo ^{[4
]}

Hamano, Takayuki ^{[5
,6
]}

Fukagawa, Masafumi ^{[7
]}

Kazama, Junichiro James ^{[8
]}

机构：

[1] Niigata City Gen Hosp, Dept Nephrol & Rheumatol, Niigata, Japan

[2] Niigata Univ, Grad Sch Med & Dent Sci, Div Clin Nephrol & Rheumatol, 1-757 Asahimachi Dori, Niigata 9518510, Japan

[3] Niigata Shirone Gen Hosp, Div Nephrol, Niigata, Japan

[4] Fukuoka Renal Clin, Fukuoka, Japan

[5] Nagoya City Univ, Grad Sch Med Sci, Dept Nephrol, Nagoya, Aichi, Japan

[6] Osaka Univ, Grad Sch Med, Dept Nephrol, Suita, Osaka, Japan

[7] Tokai Univ, Sch Med, Dept Internal Med, Div Nephrol Endocrinol & Metab, Isehara, Kanagawa, Japan

[8] Fukushima Med Univ, Div Nephrol & Hypertens, Fukushima, Japan

来源：

JOURNAL OF BONE AND MINERAL METABOLISM | 2024年 / 42卷 / 03期

关键词：

Calcimimetics; Fracture; Parathyroid hormone; Dialysis; Meta-analysis; PATIENTS RECEIVING HEMODIALYSIS; CARDIOVASCULAR-DISEASE; PARATHYROID-HORMONE; CINACALCET; RISK; ETELCALCETIDE; OUTCOMES; HIP; HOSPITALIZATION; DEATH;

D O I：

10.1007/s00774-024-01500-y

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

IntroductionThis study aimed to assess the effectiveness of calcimimetics in reducing the risk of fractures in dialysis patients with secondary hyperparathyroidism (SHPT).Material and methodsA comprehensive literature search was conducted using PubMed, Embase, and Cochrane Library for articles published through December 9, 2023. The quality of each trial was evaluated using the Cochrane Collaboration tool. Meta-analysis was performed using a random-effects model, and effect measures across studies were synthesized. The risk ratio (RR) and 95% confidence interval (CI) were used to quantify the risk of fracture.ResultsWe identified seven studies involving 6481 dialysis patients with SHPT. The administration of calcimimetics reduced fracture incidence compared to placebo or conventional treatment (RR: 0.50, 95% CI 0.29-0.88, p = 0.02). Calcimimetics demonstrated a low number needed to treat (NNT) to prevent an incident fracture (NNT: 47).ConclusionThe use of calcimimetics offers a significant benefit in reducing the risk of fractures in patients undergoing dialysis with SHPT.

引用

页码：316 / 325

页数：10

共 35 条

[1] Calcium Sensing Receptor Function Supports Osteoblast Survival and Acts as a Co-Factor in PTH Anabolic Actions in Bone [J].

Al-Dujaili, Saja A. ;

Koh, Amy J. ;

Dang, Ming ;

Mi, Xue ;

Chang, Wenhan ;

Ma, Peter X. ;

McCauley, Laurie K. .

JOURNAL OF CELLULAR BIOCHEMISTRY, 2016, 117 (07) :1556-1567

[2] Increased risk of hip fracture among patients with end-stage renal disease [J].

Alem, AM ;

Sherrard, DJ ;

Gillen, DL ;

Weiss, NS ;

Beresford, SA ;

Heckbert, SR ;

Wong, C ;

Stehman-Breen, C .

KIDNEY INTERNATIONAL, 2000, 58 (01) :396-399

[3] Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism [J].

Behets, Geert J. ;

Spasovski, Goce ;

Sterling, Lulu R. ;

Goodman, William G. ;

Spiegel, David M. ;

De Broe, Marc E. ;

D'Haese, Patrick C. .

KIDNEY INTERNATIONAL, 2015, 87 (04) :846-856

[4] Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis [J].

Block, GA ;

Martin, KJ ;

de Francisco, ALM ;

Turner, SA ;

Avram, MM ;

Suranyi, MG ;

Hercz, G ;

Cunningham, J ;

Abu-Alfa, AK ;

Messa, P ;

Coyne, DW ;

Locatelli, F ;

Cohen, RM ;

Evenepoel, P ;

Moe, SM ;

Fournier, A ;

Braun, J ;

McCary, LC ;

Zani, VJ ;

Olson, KA ;

Drüeke, TB ;

Goodman, WG .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1516-1525

[5] An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism [J].

Block, Geoffrey A. ;

Chertow, Glenn M. ;

Sullivan, John T. ;

Deng, Hongjie ;

Mather, Omar ;

Tomlin, Holly ;

Serenko, Michael .

PLOS ONE, 2019, 14 (03)

[6] Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism A Randomized Clinical Trial [J].

Block, Geoffrey A. ;

Bushinsky, David A. ;

Cheng, Sunfa ;

Cunningham, John ;

Dehmel, Bastian ;

Drueke, Tilman B. ;

Ketteler, Markus ;

Kewalramani, Reshma ;

Martin, Kevin J. ;

Moe, Sharon M. ;

Patel, Uptal D. ;

Silver, Justin ;

Sun, Yan ;

Wang, Hao ;

Chertow, Glenn M. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (02) :156-164

[7] CKD-Mineral and Bone Disorder and Risk of Death and Cardiovascular Hospitalization in Patients on Hemodialysis [J].

Block, Geoffrey A. ;

Kilpatrick, Ryan D. ;

Lowe, Kimberly A. ;

Wang, Wenli ;

Danese, Mark D. .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 8 (12) :2132-2140

[8] Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis [J].

Chertow, Glenn M. ;

Block, Geoffrey A. ;

Correa-Rotter, Ricardo ;

Drueeke, Tilman B. ;

Floege, Juergen ;

Goodman, William G. ;

Herzog, Charles A. ;

Kubo, Yumi ;

London, Gerard M. ;

Mahaffey, Kenneth W. ;

Mix, T. Christian H. ;

Moe, Sharon M. ;

Trotman, Marie-Louise ;

Wheeler, David C. ;

Parfrey, Patrick S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (26) :2482-2494

[9] Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone [J].

Coco, M ;

Rush, H .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 36 (06) :1115-1121

[10] Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism [J].

Cunningham, J ;

Danese, M ;

Olson, K ;

Klassen, P ;

Chertow, GM .

KIDNEY INTERNATIONAL, 2005, 68 (04) :1793-1800

← 1 2 3 4 →